Company description

NeuroTherapia is a privately held clinical-stage biotechnology company headquartered in Ohio, United States, focused on developing novel therapies for neuroinflammatory disorders affecting the central nervous system. The company was founded in 2015 as a spin-off from the Cleveland Clinic based on research into new approaches for treating neurological diseases driven by inflammation.

The company’s scientific approach centres on targeting microglia, the immune cells of the central nervous system that contribute to inflammation in conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and neuropathic pain. NeuroTherapia is developing orally administered small-molecule drugs designed to modulate these immune responses and protect neuronal function.

NeuroTherapia’s lead drug candidate, NTRX-07, is a highly selective cannabinoid type-2 (CB2) receptor agonist designed to reduce neuroinflammation and promote neuronal survival. Preclinical studies have demonstrated improvements in memory and cognitive function in Alzheimer’s disease models, and the therapy has also shown potential across multiple neurological disorders.

The company has completed early clinical safety studies and continues to advance its clinical development pipeline. NeuroTherapia has received funding from organisations including the Alzheimer’s Drug Discovery Foundation, Cleveland Clinic, Brain Trust Accelerator Fund and Dolby Family Ventures to support its development activities.

Key products and services

Small-molecule therapeutic development

• Oral small-molecule therapies targeting neuroinflammation
• CNS-focused drug discovery and development
• Combination therapy potential with existing treatments

Lead clinical candidate — NTRX-07

• CB2 receptor agonist targeting activated microglia
• Designed to reduce inflammation and promote neuronal survival
• Preclinical efficacy demonstrated in Alzheimer’s disease models

Neurological disease pipeline focus

• Alzheimer’s disease
• Parkinson’s disease
• Amyotrophic lateral sclerosis (ALS)
• Neuropathic pain and multiple sclerosis

Clinical development and research

• Phase I clinical safety studies completed
• Ongoing clinical development and biomarker studies
• Preclinical and translational research programmes

Platform-based neuroinflammation approach

• Microglia-targeted therapeutic strategy
• Neuroprotection and disease-modifying approach
• Expansion into additional CNS indications

Final paragraph

By focusing on neuroinflammation as a central driver of neurological disease, NeuroTherapia is developing a new class of oral therapies aimed at modifying disease progression rather than only treating symptoms. Its clinical-stage pipeline, novel microglia-targeted approach and backing from leading research institutions position the company as an emerging innovator in neurological drug development.